ClinicalTrials.gg
CompletedNCT01683409Updated Sep 30, 2019Results posted

A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

A Phase 2 interventional study of Baricitinib and Placebo in Diabetic Kidney Disease, sponsored by Eli Lilly and Company. Completed at 45 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-30.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.

Enrollment
41st of 120
130 · median 79
Started
2012
with 5 others
Phase 2
54 of 153
5 open now
Registered
60th of 153
by date

Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 41st largest by enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2012, is one of 54 in phase 2, and was the 60th registered.

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Diabetic Nephropathies with a site in United States, or all of them as a file.
02

Study summary

This is a dose ranging study to evaluate the safety and efficacy of baricitinib in the treatment of participants with mild to moderate diabetic kidney disease.

03

Conditions studied

  • Diabetic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with Type 2 diabetes treated with at least one antihyperglycemic medicine for 12 months
  • Have diabetic kidney disease and receiving one of two specific medicines used to treat high blood pressure or diabetic kidney disease for at least 3 months
  • Estimated (eGFR) of 25 to 70 milliliter per minute per 1.73 square meter (mL/min/1.73 m²) (as determined by the Chronic Kidney Disease Epidemiology Collaboration equation) and a urinary albumin/creatinine ratio (UACR) >300 milligram per gram (mg/g) and \<5000 mg/g

Exclusion criteria

Exclusion Criteria:

  • Too high blood pressure when you enter the study
  • Some specific medicines used to treat high blood pressure or diabetic kidney disease
  • Frequent high blood glucose levels
  • Renal transplant or past history of dialysis
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Had a special X-ray in the past 30 days which involved also receiving an injection of dye into the vein
  • Major surgery within 8 weeks of study entry or will require major surgery during the study
  • Some types of vaccination
  • Shingles or currently have symptoms of a cold sore
  • Serious viral, bacterial, fungal, or parasitic infection, or a urinary infection, Tuberculosis (TB)
  • (HIV) infection- the virus that causes Acquired immunodeficiency syndrome (AIDS)
  • Have or had some blood disorders, enlarged lymph glands or spleen, or some cancers.
  • Serious circulatory, breathing, liver, stomach or bowel problems, neurological or psychiatric disorders
  • Heart attack or heart failure, or a stroke
  • Other serious disorders or illnesses
  • (ECG) heart trace abnormalities
  • Alcohol or illegal drug abuse
  • Donated more than 500 mL of blood in the last 30 days (no blood donations allowed during the study)
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
130 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Administered orally, given as three placebo tablets in the morning and one placebo tablet in the evening for 24 weeks.

    Drug: Placebo

  • Experimental
    Baricitinib 0.75 mg/0.5 mg QD

    Administered orally, 0.75 mg given as one 0.75 mg tablets and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    Baricitinib 0.75 mg/0.5 mg BID

    Administered orally, 0.75 mg given as one 0.75 tablet and 2 placebo in the morning and one 0.75 mg tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one 0.5 mg tablet in the evening. Placebo tablets given to maintain blind.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    Baricitinib 1.5 mg/1 mg

    Administered orally, 1.5 mg given as two 0.75 mg tablets and 1 placebo tablet in the morning and one placebo tablet in the evening for 24 weeks or 1 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.

    Drug: Baricitinib · Drug: Placebo

  • Experimental
    Baricitinib 4 mg/2.75 mg

    Administered orally, 4 mg given as one tablet and 2 placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 2.75 mg given as two 1 mg tablets and one 0.75 mg tablet in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.

    Drug: Baricitinib · Drug: Placebo

Interventions

  • Administered orally

    Also known as: LY3009104, INCB28050

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 24

    UACR is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine. The least squares mean (LS mean) are from mixed model repeated measures (MMRM) analyses which include treatment, baseline estimated Glomerular Filtration Rate (eGFR) group (higher: 50 to 70 mL/min/1.73m² and lower: 25 to \<50 mL/min/1.73m²), visit, treatment-by-visit interaction, baseline UACR, and baseline UACR-by-visit interaction.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in Urinary Monocyte Chemotactic Protein 1 (MCP-1)/Creatinine Ratio

    Time frame: Baseline, Week 24

  2. Change From Baseline in Creatinine Clearance at Week 24

    Creatinine clearance is the amount of creatinine cleared from kidney within 24 hours. The LS mean was from MMRM analyses which included treatment, baseline eGRF group, visit, treatment-by-visit interaction, baseline Creatinine Clearance, and baseline Creatinine Clearance-by-visit interaction.

    Time frame: Baseline, Week 24

  3. Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 24

    EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state. The second part is assessed using a visual analog scale (VAS) that ranged from 0 to 100mm, where 0 is the worst health you can imagine and 100 is the best health you can imagine. The LS means are analyzed using an analysis of covariance (ANCOVA) model with treatment, baseline eGFR group, and baseline VAS score or baseline health state index score as covariates.

    Time frame: Baseline, Week 24

  4. Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady State (AUC,ss)

    Evaluable pharmacokinetic concentrations from the 2-week, 4-week, 8-week, 12-week, 16-week, 20-week and 24-week time points were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.

    Time frame: Weeks 2 and 4 (1-2 hours postdose), 8 (3-6 hours postdose), 12 (in fasted state), 16 and 20 (6-9 hours postdose), 24 (in fasted state)

07

Results

Posted Jul 2, 2017

Participant flow

The study included a 24-week treatment period and a 4- to 8-week washout period where study drug was discontinued. Time to loss-of-treatment benefit (defined as a failure to maintain a 30% decrease in UACR from baseline) was evaluated at Week 28. Participants who maintained treatment benefit were followed for an additional 4 weeks.

Treatment Period (Weeks 1-24)
Participant flow — Treatment Period (Weeks 1-24)
MilestonePlaceboBaricitinib 0.75 mg/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mgBaricitinib 4 mg/2.75 mg
Started2725272625
Received at least one dose of study drug2725262625
Completed2721262423
Not completed04122
Withdrew: Inappropriately enrolled00100
Withdrew: Adverse event03011
Withdrew: Lost to follow-up01000
Withdrew: Withdrawal by subject00011
Washout Period 1 (Weeks 25-28)
Participant flow — Washout Period 1 (Weeks 25-28)
MilestonePlaceboBaricitinib 0.75 mg/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mgBaricitinib 4 mg/2.75 mg
Started2721262423
Completed2417252220
Not completed34123
Withdrew: Lost to follow-up00100
Withdrew: Protocol violation10010
Withdrew: Withdrawal by subject10001
Withdrew: Physician decision10000
Withdrew: Adverse event04012
Washout Period 2 (Weeks 29-32)
Participant flow — Washout Period 2 (Weeks 29-32)
MilestonePlaceboBaricitinib 0.75 mg/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mgBaricitinib 4 mg/2.75 mg
Started668612
Completed66769
Not completed00103
Withdrew: Adverse event00003
Withdrew: Physician decision00100

Outcome measures

PrimaryChange From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 24

UACR is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine. The least squares mean (LS mean) are from mixed model repeated measures (MMRM) analyses which include treatment, baseline estimated Glomerular Filtration Rate (eGFR) group (higher: 50 to 70 mL/min/1.73m² and lower: 25 to \<50 mL/min/1.73m²), visit, treatment-by-visit interaction, baseline UACR, and baseline UACR-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · milligram/gram (mg/g)
Change From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 24
milligram/gram (mg/g)PlaceboBaricitinib 0.75 mg/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mgBaricitinib 4 mg/2.75 mg
Change From Baseline in Urinary Albumin/Creatinine Ratio (UACR) at Week 241.12 ± 0.1720.87 ± 0.1550.85 ± 0.1310.91 ± 0.1430.66 ± 0.111
SecondaryChange From Baseline in Urinary Monocyte Chemotactic Protein 1 (MCP-1)/Creatinine Ratio
Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Creatinine Clearance at Week 24

Creatinine clearance is the amount of creatinine cleared from kidney within 24 hours. The LS mean was from MMRM analyses which included treatment, baseline eGRF group, visit, treatment-by-visit interaction, baseline Creatinine Clearance, and baseline Creatinine Clearance-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · milliliter/minute (mL/min)
Change From Baseline in Creatinine Clearance at Week 24
milliliter/minute (mL/min)PlaceboBaricitinib 0.75 mg/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mgBaricitinib 4 mg/2.75 mg
Change From Baseline in Creatinine Clearance at Week 240.93 ± 0.0701.09 ± 0.1040.86 ± 0.0690.86 ± 0.0690.080 ± 0.066
SecondaryChange From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 24

EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state. The second part is assessed using a visual analog scale (VAS) that ranged from 0 to 100mm, where 0 is the worst health you can imagine and 100 is the best health you can imagine. The LS means are analyzed using an analysis of covariance (ANCOVA) model with treatment, baseline eGFR group, and baseline VAS score or baseline health state index score as covariates.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 24
Units on a ScalePlaceboBaricitinib 0.75 mg/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mgBaricitinib 4 mg/2.75 mg
Index Score (UK Algorithm) Week 240.00 ± 0.03-0.03 ± 0.03-0.01 ± 0.03-0.04 ± 0.030.00 ± 0.03
Index Score (US Algorithm) Week 240.00 ± 0.02-0.03 ± 0.020.00 ± 0.02-0.03 ± 0.020.00 ± 0.02
Self-Perceived Health Score2.62 ± 2.94-1.97 ± 3.020.28 ± 2.95-5.66 ± 2.960.37 ± 3.02
SecondaryPharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady State (AUC,ss)

Evaluable pharmacokinetic concentrations from the 2-week, 4-week, 8-week, 12-week, 16-week, 20-week and 24-week time points were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.

Time frame:
Weeks 2 and 4 (1-2 hours postdose), 8 (3-6 hours postdose), 12 (in fasted state), 16 and 20 (6-9 hours postdose), 24 (in fasted state)
Reported as:
Mean · nanomole*hour (nM*hr)
Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady State (AUC,ss)
nanomole*hour (nM*hr)Baricitinib 0.75 mg/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mgBaricitinib 4 mg/2.75 mg
Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady State (AUC,ss)198 ± 89.9286 ± 92.4388 ± 1511250 ± 577

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/27 (7.4%)18/27 (66.7%)
Baricitinib 0.75 mg/0.5 mg QD—0/25 (0%)18/25 (72%)
Baricitinib 0.75 mg/0.5 mg BID—2/26 (7.7%)17/26 (65.4%)
Baricitinib 1.5 mg/1 mg—2/26 (7.7%)19/26 (73.1%)
Baricitinib 4 mg/2.75 mg—6/25 (24%)23/25 (92%)
Placebo - Washout 1—0/27 (0%)5/27 (18.5%)
Baricitinib 0.75 mg/0.5 mg QD - Washout 1—0/21 (0%)4/21 (19%)
Baricitinib 0.75 mg/0.5 mg BID - Washout 1—0/26 (0%)4/26 (15.4%)
Baricitinib 1.5 mg/1 mg - Washout 1—0/24 (0%)7/24 (29.2%)
Baricitinib 4 mg/2.75 mg - Washout 1—0/23 (0%)8/23 (34.8%)
Placebo Washout 2—0/6 (0%)1/6 (16.7%)
Baricitinib 0.75 mg/0.5 mg QD - Washout 2—0/6 (0%)2/6 (33.3%)
Baricitinib 0.75 mg/0.5 mg BID - Washout 2—1/8 (12.5%)1/8 (12.5%)
Baricitinib 1.5 mg/1 mg - Washout 2—0/6 (0%)0/6 (0%)
Baricitinib 4 mg/2.75 mg - Washout 2—0/12 (0%)3/12 (25%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboBaricitinib 0.75 mg/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mgBaricitinib 4 mg/2.75 mgPlacebo - Washout 1Baricitinib 0.75 mg/0.5 mg QD - Washout 1Baricitinib 0.75 mg/0.5 mg BID - Washout 1Baricitinib 1.5 mg/1 mg - Washout 1Baricitinib 4 mg/2.75 mg - Washout 1Placebo Washout 2Baricitinib 0.75 mg/0.5 mg QD - Washout 2Baricitinib 0.75 mg/0.5 mg BID - Washout 2Baricitinib 1.5 mg/1 mg - Washout 2Baricitinib 4 mg/2.75 mg - Washout 2
PancreatitisGastrointestinal disorders1/270/250/260/260/250/270/210/260/240/230/60/61/80/60/12
HypoglycaemiaMetabolism and nutrition disorders0/270/250/260/262/250/270/210/260/240/230/60/60/80/60/12
AnaemiaBlood and lymphatic system disorders0/270/250/260/261/250/270/210/260/240/230/60/60/80/60/12
Staphylococcal infectionInfections and infestations0/270/250/260/261/250/270/210/260/240/230/60/60/80/60/12
DehydrationMetabolism and nutrition disorders0/270/250/260/261/250/270/210/260/240/230/60/60/80/60/12
HyperkalaemiaMetabolism and nutrition disorders0/270/250/260/261/250/270/210/260/240/230/60/60/80/60/12
Aortic valve incompetenceCardiac disorders0/270/250/261/260/250/270/210/260/240/230/60/60/80/60/12
Mitral valve incompetenceCardiac disorders0/270/250/261/260/250/270/210/260/240/230/60/60/80/60/12
Vitreous haemorrhageEye disorders0/270/251/260/260/250/270/210/260/240/230/60/60/80/60/12
Anaphylactic reactionImmune system disorders0/270/250/261/260/250/270/210/260/240/230/60/60/80/60/12
Most frequent other events
Showing 10 of 166
Most frequent other events
EventPlaceboBaricitinib 0.75 mg/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mgBaricitinib 4 mg/2.75 mgPlacebo - Washout 1Baricitinib 0.75 mg/0.5 mg QD - Washout 1Baricitinib 0.75 mg/0.5 mg BID - Washout 1Baricitinib 1.5 mg/1 mg - Washout 1Baricitinib 4 mg/2.75 mg - Washout 1Placebo Washout 2Baricitinib 0.75 mg/0.5 mg QD - Washout 2Baricitinib 0.75 mg/0.5 mg BID - Washout 2Baricitinib 1.5 mg/1 mg - Washout 2Baricitinib 4 mg/2.75 mg - Washout 2
AnaemiaBlood and lymphatic system disorders1/271/251/262/267/250/270/210/260/240/230/60/60/80/60/12
NasopharyngitisInfections and infestations1/274/254/264/263/250/270/210/260/240/230/61/60/80/60/12
Respiratory tract infectionInfections and infestations0/270/250/260/260/250/270/210/260/240/231/60/60/80/60/12
GoutMetabolism and nutrition disorders0/271/250/260/260/250/270/210/260/240/230/61/60/80/60/12
HypoglycaemiaMetabolism and nutrition disorders4/270/250/260/260/250/270/210/260/241/230/60/60/80/60/12
VertigoEar and labyrinth disorders1/270/250/260/260/250/270/210/260/240/230/60/61/80/60/12
Head bangingPsychiatric disorders0/270/250/260/260/250/270/210/260/240/230/60/61/80/60/12
NauseaGastrointestinal disorders0/272/250/261/263/250/270/210/261/240/230/60/60/80/60/12
Blood creatine phosphokinase increasedInvestigations2/271/251/261/263/250/270/210/260/240/230/60/60/80/60/12
Blood creatinine increasedInvestigations0/272/250/260/263/250/270/210/260/240/230/60/60/80/60/12

Baseline characteristics

All participants that received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)PlaceboBaricitinib 0.75/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mg QDBaricitinib 4 mg/2.75 mgTotal
Mean64 ± 9.061 ± 10.064 ± 8.361 ± 10.463 ± 7.863 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBaricitinib 0.75/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mg QDBaricitinib 4 mg/2.75 mgTotal
Female78551035
Male201721211594
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBaricitinib 0.75/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mg QDBaricitinib 4 mg/2.75 mgTotal
Hispanic or Latino4467425
Not Hispanic or Latino2321201921104
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBaricitinib 0.75/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mg QDBaricitinib 4 mg/2.75 mgTotal
American Indian or Alaska Native222219
Asian141212111160
Native Hawaiian or Other Pacific Islander000011
Black or African American2730315
White84913943
More than one race100001
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(Participants)PlaceboBaricitinib 0.75/0.5 mg QDBaricitinib 0.75 mg/0.5 mg BIDBaricitinib 1.5 mg/1 mg QDBaricitinib 4 mg/2.75 mgTotal
Puerto Rico010001
United States141314141368
Japan111010101152
Mexico212218
08

Study locations

45 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lancaster, California 93534, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Diego, California 92103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Torrance, California 90502, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lakewood, Colorado 80227, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Lauderdale, Florida 33316, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32258, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33173, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampa, Florida 33614, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Augusta, Georgia 30909, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Honolulu, Hawaii 96814, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Meridian, Idaho 83642, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gurnee, Illinois 60031, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Peoria, Illinois 60603, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Evansville, Indiana 47713, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Topeka, Kansas 66606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rockville, Maryland 20852, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ann Arbor, Michigan 48109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Detroit, Michigan 48236, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pontiac, Michigan 48341, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Missouri 65807, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Billings, Montana 59101, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashua, New Hampshire 03063, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albany, New York 12209, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10021, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosedale, New York 11422, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winston-Salem, North Carolina 27103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bethlehem, Pennsylvania 18017, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19102, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sumter, South Carolina 29150, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chattanooga, Tennessee 37408, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77030, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spokane, Washington 99204, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wenatchee, Washington 98801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 830-0011, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 004-0053, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ibaragi, 305-0812, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ibaraki, 311-0113, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 530-0001, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 103-0027, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Merida, 97070, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 03300, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ponce, 00716, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rio Piedras, 00936, Puerto Rico
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Sep 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 2 years 10 months after primary completion. A results delay was requested in Jan 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2012
First posted
Sep 11, 2012
Start
Aug 2012
Primary completionActual
Sep 2014
CompletionActual
Nov 2014
Results delay requested
Jan 16, 2015
Results first posted
Jul 2, 2017
Last update
Sep 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01683409
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Sep 11, 2012
Start date
Aug 2012
Primary completion
Sep 2014
Completion
Nov 2014
Results posted
Jul 2, 2017
Last update
Sep 30, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion